Showing 461-470 of 3714 results for "".
- FDA Approves Dermavant's Vtama for Psoriasishttps://practicaldermatology.com/news/fda-approves-dermavants-vtama-for-psoriasis/2461205/FDA has approved Vtama® (tapinarof) cream, 1%, an aryl hydrocarbon receptor agonist from Dermavant for the topical treatment of plaque psoriasis in adults. Vtama cream is the first and only FDA-approved steroid-free topical medication in its class. Dermavant says it will have product available in…
- Healthy-appearing Lupus Skin Predisposed to Flares, Rasheshttps://practicaldermatology.com/news/healthy-appearing-lupus-skin-predisposed-to-flares-rashes/2461181/Normal-appearing skin of lupus patients contains the same inflammatory signals that are detected when the skin develops a rash – sometimes at even higher levels, according to a study in Science Translational Medicine. “This really starts to piece the puzzle together of how inflammation seen in lup…
- New Analysis Ranks Tremfya Highest Among PsA Treatments for Skin Clearancehttps://practicaldermatology.com/news/new-analysis-ranks-tremfya-highest-among-psa-treatments-for-skin-clearance/2461054/Tremfya® (guselkumab) ranks highest for skin clearance, based on Psoriasis (PsO) Area Severity Index (PASI) 90 response, among 23 psoriatic arthritis (PsA) treatment regimens, results of a newly reported Network Meta-Analysis (NMA) show. In terms of joint inflammation improvement, both Tremfya dosi…
- Mount Sinai Awarded $4 Million Grant to Launch Skin Biology and Diseases Resource-based Centerhttps://practicaldermatology.com/news/mount-sinai-awarded-4-million-grant-to-launch-skin-biology-and-diseases-resource-based-center/2460963/The Icahn School of Medicine at Mount Sinai is establishing a Skin Biology and Diseases Resource-based Center (SBDRC), funded by a $4 million, five-year P30 grant from the National Institutes of Health and the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). The Moun…
- Allergan Aesthetics Continues Partnership with Girls Inc.https://practicaldermatology.com/news/allergan-aesthetics-continues-partnership-with-girls-inc/2460869/Allergan Aesthetics is starting its third consecutive year of partnership with Girls Inc. and debuting Empowering Confidence Workshops, a nationwide mentoring initiative. Based on a 2020 Girls Inc. report, many girls have a hard time picturing themselves in science, technology, engineering and mat…
- Fat Grafting Shows Promise for Cancer Patients with Radiation-induced Skin Injuryhttps://practicaldermatology.com/news/fat-grafting-shows-promise-for-cancer-patients-with-radiation-induced-skin-injury/2460730/As cancer survival rates improve, more people are living with the aftereffects of cancer treatment including chronic radiation-induced skin injury. Fat grafting procedures may unleash the healing and regenerative power of the body's natural adipose stem cells (ASCs). "Preliminary evidence suggests…
- AAD Honors Dr. Ginette Okoye with National Patient Care Hero Award for COVID-19 Testing Workhttps://practicaldermatology.com/news/aad-honors-dr-ginette-okoye-with-national-patient-care-hero-award-for-covid-19-testing-work/2460729/The American Academy of Dermatology (AAD) named board-certified dermatologist Ginette Okoye, MD, FAAD a Patient Care Hero for establishing a dedicated COVID-19 community testing site in a historically underserved neighborhood in northeast Washington, DC. Amid the initial surge in COVID-19 cases la…
- Label Update for Enstilar Foam Highlights Long-Term Use in Adultshttps://practicaldermatology.com/news/label-update-for-enstilar-foam-highlights-long-term-use-in-adults/2460575/The US Prescribing Information (USPI) for Enstilar® (calcipotriene and betamethasone dipropionate) Foam from LEO Pharma A/S now includes data on long-term use in adults with plaque psoriasis. The update results from the FDA approving a supplemental New Drug Application (sNDA). The sNDA submission …
- Amytrx Therapeutics Comes Out of the Gate Strong with Lead Program AMTX-100, Clinical Development Planshttps://practicaldermatology.com/news/amytrx-therapeutics-comes-out-of-the-gate-strong-with-lead-program-amtx-100-clinical-development-plans/2460531/Amytrx Therapeutics, Inc. is on the move. Founded in 2014, Nashville-based Amytrx is developing novel therapies for inflammatory diseases with lead program AMTX-100 currently in clinical development for dermatologic indications. AMTX-100 is a new anti-inflammatory therapeutic platform, which has …
- New York’s Mount Sinai Health System Names New Chair of Dermatology and New Dean For Clinical Therapeuticshttps://practicaldermatology.com/news/new-yorks-mount-sinai-health-system-names-new-chair-of-dermatology-and-new-dean-for-clinical-therapeutics/2460486/Emma Guttman-Yassky, MD, PhD, is the new Chair of the Kimberly and Eric J. Waldman Department of Dermatology at the Icahn School of Medicine at Mount Sinai and the Mount Sinai Health System. She will be the first woman to serve as Chair of a Department of Dermatology in New York City. She is curre…